Group 1 - The chairman and several executives of *ST Sailong have collectively resigned due to a change in the company's control, with all nine members of the fourth board submitting resignation letters [1] - Cai Nanguai, the chairman and president, will continue to hold other positions within the company after resigning from his roles, and he holds 67.51 million shares, representing a 47.23% stake in a major shareholder [1] - The board expressed sincere gratitude for Cai Nanguai's significant contributions to the company's strategic decision-making, compliance governance, and stable operations during his tenure [1] Group 2 - On July 15, *ST Sailong announced a forecast for the first half of the year, expecting a net loss attributable to shareholders of between 13 million to 18 million yuan, compared to a profit of 1.7647 million yuan in the same period last year [2]

*ST赛隆（002898）8月10日晚间公告称，因公司控制权已发生变更，公司于近日收到董事长兼总裁蔡南 桂，董事唐霖，董事兼常务副总裁刘达文，董事兼副总裁李剑峰，董事、副总裁、董事会秘书张旭，董 事邓拥军，独立董事潘传云，独立董事陈小辛，独立董事李公奋，副总裁王星递交的辞职报告。 值得一提的是，目前，*ST赛隆第四届董事会共有9名董事。这意味着，*ST赛隆第四届董事会的所有成 员均递交了辞职报告。 其中，蔡南桂申请辞去董事长、董事、总裁、战略决策委员会主任委员职务，辞职后蔡南桂将继续担任 公司其他职务。截至本公告披露日，蔡南桂不存在应履行而未履行的承诺事项。蔡南桂现持有公司股份 6751.27万股，持有公司股东珠海横琴新区赛隆聚智投资有限公司47.23%股权。 公司还公告，公司于2025年8月10日召开了第四届董事会第十次会议，审议通过了《关于聘任公司总裁的 议案》，公司董事会同意聘任陈科担任公司总裁，任期自本次董事会会议审议通过之日起至第四届董事 会届满之日止。 简历显示，贾晋斌于1970年出生，医学博士、金融学博士、外科学博士后，山西医科大学客座教授，博 士生导师，主任药师，中国国籍，有香港居民身份证。曾 ...

Core Viewpoint - *ST Sailong (002898) has announced a change in control, leading to the resignation of all members of its fourth board of directors, including key executives such as Chairman and President Cai Nanguai [1][3][4]. Group 1: Board Resignation - The entire fourth board of directors, consisting of 9 members, has submitted resignation reports [3]. - Cai Nanguai, the founder and Chairman, will continue to hold other positions within the company after resigning from his current roles [3][4]. - The resignations will result in the board's membership falling below the minimum required by the company's articles of association, necessitating the continuation of their duties until new directors are elected [4]. Group 2: New Board Candidates - The company has nominated new candidates for the fourth board of directors, including 贾晋斌, 陈科, 陈顿斐, 张光扬, 陈榕辉, 李童瑶 as non-independent directors, and 王淑芳, 张建民, 张凯 as independent directors [4]. - The term for the newly nominated directors will last until the end of the current board's term [4]. Group 3: Financial Performance - *ST Sailong expects a net loss of between 13 million to 18 million yuan for the first half of the year, compared to a profit of 176.47 thousand yuan in the same period last year [7]. - The basic earnings per share are projected to be a loss of 0.0739 to 0.1023 yuan, contrasting with earnings of 0.0100 yuan per share in the previous year [7]. - On August 8, the stock price of *ST Sailong reached a closing price of 16.81 yuan per share, with a total market capitalization of 2.959 billion yuan [7][8].

Focus Events - Zhongxing Microtechnology has restarted its IPO process and is seeking to list on the Sci-Tech Innovation Board, with Galaxy Securities as the counseling institution [1] Corporate Dynamics - Industrial Fulian reported a revenue of 360.76 billion yuan for the first half of 2025, a year-on-year increase of 35.6%, and a net profit of 12.11 billion yuan, up 38.6%, both reaching historical highs [20] - Wan Tong Development plans to invest 854 million yuan to acquire a 62.98% stake in Beijing Shudu Information Technology Co., making it a subsidiary [23] - *ST Sailong announced a complete board reshuffle due to a change in control, with the resignation of multiple board members and the appointment of a new president [24] - Springlight Technology intends to invest no more than 1 billion yuan to establish a project for producing 8 million clean electrical appliances annually [25] - Changqing Co. reported a net profit of 42.28 million yuan for the first half of 2025, a year-on-year increase of 117.75% [26] - Yanjing Beer disclosed a net profit of 1.103 billion yuan for the first half of 2025, reflecting a 45.45% year-on-year growth [29] Industry Dynamics - The State Council has introduced policies to support the artificial intelligence industry in Henan, including the establishment of a 3 billion yuan AI industry fund [11] - Beijing Economic and Technological Development Zone released ten measures to support the development of embodied intelligent robots [15] - The establishment of the Hubei Brain-Computer Interface Industry Innovation Development Alliance aims to foster collaboration among academia, industry, and healthcare [19]

Core Viewpoint - *ST Sailong, a pharmaceutical company engaged in the full industry chain of drug intermediates, raw materials, formulations, and technical services, faces delisting risk due to negative financial performance in 2024, with a revenue of 264 million yuan and a net profit of -33.14 million yuan [2] Group 1: Financial Performance - In 2024, *ST Sailong achieved an operating income of 264 million yuan and a net profit attributable to shareholders of -33.14 million yuan [2] - The company reported negative values for total profit, net profit, and net profit after deducting non-recurring gains and losses, with operating income below 300 million yuan [2] Group 2: Share Transfer Agreement - On May 18, 2025, the controlling shareholders Cai Nanguai and Tang Lin signed a share transfer agreement with Hainan Yayi, transferring 14.16% of the company's shares, totaling 24.9122 million shares at a price of 8 yuan per share, amounting to 199 million yuan [2] - Following the completion of the share transfer, the controlling shareholder will change from Cai Nanguai and Tang Lin to Hainan Yayi, which currently has no actual controller, resulting in *ST Sailong having no actual controller [2] Group 3: Board Changes - On August 10, 2025, *ST Sailong announced the resignation of several board members, including the chairman and president Cai Nanguai, and the appointment of new non-independent board member candidates [3] - The board approved the appointment of Chen Ke as the new president, who has a background in accounting and investment [4]

Core Viewpoint - *ST Sailong (002898) has undergone a change in control, leading to the resignation of all members of its fourth board of directors, including key executives and board members [1][3][4]. Group 1: Board Resignations - The entire fourth board of directors, consisting of 9 members, has submitted resignation letters, including Chairman and President Cai Nanguai [3][4]. - Cai Nanguai will continue to hold other positions within the company despite resigning from his roles as Chairman, President, and Strategic Decision Committee Chair [3]. - Director Tang Lin has also resigned from all positions, holding 722.39 million shares as of the announcement date [3]. Group 2: New Board Candidates - The company has proposed new candidates for the fourth board of directors, including 贾晋斌, 陈科, and others as non-independent director candidates, and 王淑芳, 张建民, and 张凯 as independent director candidates [4]. Group 3: Management Changes - The board has approved the appointment of 陈科 as the new President, effective immediately following the board meeting [5]. - 陈科 has a background in accounting and investment management, having worked with KPMG and other firms [5]. Group 4: Stock Performance - Following the announcement, *ST Sailong's stock price reached a closing price of 16.81 CNY per share, marking a 5% increase and a total market capitalization of 29.59 billion CNY [5]. - The stock has seen a year-to-date increase of over 70%, attributed to merger and acquisition speculation [5].

值得一提的是，目前，*ST赛隆第四届董事会共有9名董事。这意味着，*ST赛隆第四届董事会的所有成员均递 交了辞职报告。 集体辞职。 *ST赛隆（002898）8月10日晚间公告称，因公司控制权已发生变更，公司于近日收到董事长兼总裁蔡南桂， 董事唐霖，董事兼常务副总裁刘达文，董事兼副总裁李剑峰，董事、副总裁、董事会秘书张旭，董事邓拥军， 独立董事潘传云，独立董事陈小辛，独立董事李公奋，副总裁王星递交的辞职报告。 其中，蔡南桂申请辞去董事长、董事、总裁、战略决策委员会主任委员职务，辞职后蔡南桂将继续担任公司其 他职务。截至本公告披露日，蔡南桂不存在应履行而未履行的承诺事项。蔡南桂现持有公司股份6751.27万 股，持有公司股东珠海横琴新区赛隆聚智投资有限公司47.23%股权。 *ST赛隆在公告中指出，蔡南桂作为公司创始人、董事长，在任期间对公司的战略决策和合规治理、稳健经营 等方面做出了重大贡献，公司董事会对蔡南桂为公司发展所做出的卓越贡献表示诚挚的敬意和衷心感谢。 此外，唐霖申请辞去董事、战略决策委员会委员、审计委员会委员职务，辞去上述职务后唐霖不再担任公司任 何职务。截至本公告披露日，唐霖不存在应履行而未履行 ...

Group 1 - The company held its fourth board meeting on August 10, 2025, with all nine directors present, confirming compliance with legal and regulatory requirements [1] - Due to a change in control, several non-independent directors resigned, and new candidates for non-independent director positions were nominated and approved by the board [1][2] - The nominated non-independent directors include 贾晋斌, 陈科, 陈顿斐, 张光扬, 陈榕辉, and 李童瑶, all receiving unanimous support from the board [2][3] Group 2 - Independent directors also resigned due to the change in control, leading to the nomination of 王淑芳, 张建民, and 张凯 as independent director candidates [3][4] - All independent director candidates received unanimous approval from the board and will be presented for shareholder vote at the upcoming extraordinary general meeting [4][5] - The company appointed 陈科 as the new president, with the decision also receiving unanimous support from the board [5] Group 3 - The company plans to revise its articles of association and related governance documents in accordance with new legal requirements, with the proposed changes to be submitted for shareholder approval [5][6] - The board's decisions and nominations will be subject to cumulative voting at the upcoming extraordinary general meeting [3][4][6]

Core Points - The independent director candidate, Zhang Kai, has committed to participate in the latest independent director training to fulfill his responsibilities [1] Group 1 - The independent director candidate has not yet obtained the independent director training certificate recognized by the Shenzhen Stock Exchange as of the date of the commitment letter [1] - The commitment was made following the nomination by the controlling shareholder and approval by the company's fourth board of directors' tenth meeting [1] - The candidate aims to enhance his ability to perform independent director duties through this training [1]

证券代码：002898 证券简称：*ST 赛隆 公告编号：2025-053 赛隆药业集团股份有限公司 独立董事候选人声明与承诺 声明人 张建民作为赛隆药业集团股份有限公司第四届董事会独立董事候选 人，已充分了解并同意由提名人海南雅亿共赢科技合伙企业（有限合伙）提名为 赛隆药业集团股份有限公司（以下简称该公司）第四届董事会独立董事候选人。 现公开声明和保证，本人与该公司之间不存在任何影响本人独立性的关系，且符 合相关法律、行政法规、部门规章、规范性文件和深圳证券交易所业务规则对独 立董事候选人任职资格及独立性的要求，具体声明并承诺如下事项： 一、本人已经通过赛隆药业集团股份有限公司第四届董事会提名委员会或者 独立董事专门会议资格审查，提名人与本人不存在利害关系或者其他可能影响独 立履职情形的密切关系。 如否，请详细说明：______________________________ 三、本人符合中国证监会《上市公司独立董事管理办法》和深圳证券交易所 业务规则规定的独立董事任职资格和条件。 是 □ 否 如否，请详细说明：______________________________ 四、本人符合该公司章程规定的独立董 ...